Pα+ Psychedelic Bulletin #215: FDA’s single-trial approval shift, Freedom to Heal Act right-to-try push, and Compass Q1 readout plans

Single Phase 3 approvals are emerging as a potential FDA policy shift, with implications for how psychedelic drug sponsors might structure pivotal trials and timing their new drug applications. The Freedom to Heal Act is highlighted as a legislative effort intended to close the federal “right to try” gap for psychedelics, aiming to improve access pathways for patients while approvals and development progress. The bulletin also notes Compass’s plans for Q1, offering context on upcoming updates around its psilocybin program, including how trial design scale and evidence packages may affect payor and provider confidence if approvals arrive under evolving regulatory expectations.